Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Travere Therapeutics logo — In rare for life.

Travere Therapeutics

In rare for life.

Founded 2020 United States San Diego, United States 504 employees Post Ipo Equity Biotechnology, Health Care

General Information

Company Name Travere Therapeutics
Founded Year 2020
Location United States San Diego, United States +3
Founders / Decision Makers
Team member Team member
Employees 504
Industries Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when Travere Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Travere Therapeutics

Travere Therapeutics, specializing in biotechnology and health care, focuses on identifying, developing, and delivering life-changing therapies for individuals battling rare diseases. Established in 2020, the company's mission is encapsulated in its slogan, "In rare for life," reflecting its dedication to making a meaningful impact in the field of rare disease treatment. Their commitment to the community is evident through their dedication to transparency and ethical conduct, as outlined in their Community Guidelines. The most recent significant milestone for Travere Therapeutics was a Post-IPO Equity investment on 07 November 2024. This marked an important stage in the company's growth and development, signifying the continued confidence and support from investors in their mission. As of now, specific details regarding the investors involved in this round of investment are not publicly available. Travere Therapeutics' innovative approach and steadfast dedication to addressing the unmet needs of individuals facing rare diseases position them as a noteworthy player in the biotechnology and health care sectors, attracting interest and support from the investment community.

Taxonomy: rare disease therapies, nephrology, hepatology, metabolism disorders, genetic testing, cholestasis, patient advocacy, FDA-approved therapies, biopharmaceuticals

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 07 Nov 2024
Post-IPO Equity •••••• - 28 Feb 2023
Post-IPO Debt •••••• - 08 Mar 2022
Post-IPO Equity •••••• - 10 Feb 2021
Post-IPO Equity •••••• - 19 Mar 2015

View All 8 Funding Rounds

Travere Therapeutics Alternatives & Competitors

Travere Therapeutics vs
Allogene Therapeutics
Allogene Therapeutics United States

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy

IPO
214 employees
Biotechnology
Compare Travere Therapeutics vs Allogene Therapeutics
Travere Therapeutics vs
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals

Developing innovative therapies to treat and cure rare metabolic diseases

Post Ipo Debt
25 employees
Biotechnology, Health Care
Compare Travere Therapeutics vs Eiger BioPharmaceuticals
Travere Therapeutics vs
S1 Biopharma
S1 Biopharma

Leading developer of first-in-class drugs for sexual dysfunction and hypoactive sexual desire disord...

4 employees
Biopharma, Biotechnology
Also compare with: Travere Therapeutics vs MorphoSys MorphoSys

FAQ About Travere Therapeutics

In rare for life.
Travere Therapeutics was founded in 2020.
Travere Therapeutics is headquartered in San Diego, United States.
Travere Therapeutics operates in the following industries: Biotechnology, Health Care.
Travere Therapeutics has approximately 504 employees.
Travere Therapeutics has completed 8 funding rounds. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Travere Therapeutics include Allogene Therapeutics, Eiger BioPharmaceuticals, S1 Biopharma, MorphoSys, Xero. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Travere Therapeutics and Allogene Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Travere Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes